Exicure, Inc.
Exicure, Inc. (Nasdaq: XCUR) is a company exploring strategic transactions, including acquisitions, partnerships and other arrangements, and seeking financing to support these efforts. It has no current revenue source and no active research, development, manufacturing, sales or marketing operations. Historically,… From the company’s description.
Over the twelve months to Jun 30, 2026, Exicure, Inc. reported a net loss of $8.28M. Operations used $6.70M in cash. In fiscal 2025, it reported a net loss of $4.95M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Exicure, Inc. does
In the company’s own words
Exicure, Inc. (Nasdaq: XCUR) is a company exploring strategic transactions, including acquisitions, partnerships and other arrangements, and seeking financing to support these efforts. It has no current revenue source and no active research, development, manufacturing, sales or marketing operations. Historically, Exicure developed nucleic acid therapies and spherical nucleic acid technology; it sold its biotechnology intellectual property, research programs and clinical assets to Flashpoint Therapeutics in 2024, with any future value from those assets primarily dependent on uncertain royalties or license fees. In January 2025, Exicure acquired GPCR Therapeutics USA and entered a license and collaboration agreement covering GPCR technologies; the subsidiary’s clinical program combines GPC-100 and propranolol to mobilize stem cells in multiple myeloma patients. The company has no reportable business segments. It had eight full-time employees as of December 31, 2025, focused on finance and general management. Exicure traces its current business to a 2017 merger with its predecessor, a biotechnology company formed in 2011. Its website is www.exicuretx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CHICAGO, IL
- Fiscal year end
- December
- CIK
- 1698530
- SIC
- 2834
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Exicure, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Exicure, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Exicure, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Exicure, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Exicure, Inc.'s last four quarterly filings that the numbers alone won't show?”